Christopher M Halloran
Overview
Explore the profile of Christopher M Halloran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmer D, Jackson R, Springfeld C, Ghaneh P, Rawcliffe C, Halloran C, et al.
J Clin Oncol
. 2024 Dec;
:JCO2401118.
PMID: 39637340
Purpose: The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival...
2.
Bannone E, Cattelani A, Corvino G, Marchetti A, Andreasi V, Fermi F, et al.
Ann Surg
. 2024 Oct;
PMID: 39435540
Objective: To validate the ISGPS definition and grading system of PPAP after pancreatoduodenectomy (PD). Summary Background Data: In 2022, the International Study Group for Pancreatic Surgery (ISGPS) defined post-pancreatectomy acute...
3.
Barreto S, Strobel O, Salvia R, Marchegiani G, Wolfgang C, Werner J, et al.
Ann Surg
. 2024 Jul;
281(3):417-429.
PMID: 39034920
Objective: To develop a universally accepted complexity and experience grading system to guide the safe implementation of robotic and laparoscopic minimally invasive pancreatoduodenectomy (MIPD). Background: Despite the perceived advantages of...
4.
Halloran C, Neoptolemos J, Jackson R, Platt K, Psarelli E, Reddy S, et al.
Ann Surg Open
. 2022 Oct;
3(3):e198.
PMID: 36199490
Importance: Complications driven by POPF following pancreatic cancer resection may hinder adjuvant therapy, shortening survival. BA may reduce complications compared to CWA, improving the use of adjuvant therapy and prolonging...
5.
Stott M, Oldfield L, Hale J, Costello E, Halloran C
Fac Rev
. 2022 May;
11:9.
PMID: 35509672
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer deaths worldwide. Over 90% of patients die within 1 year of diagnosis. Deaths from PDAC are...
6.
Bellomo G, Rainer C, Quaranta V, Astuti Y, Raymant M, Boyd E, et al.
Gut
. 2022 Jan;
71(11):2284-2299.
PMID: 35022267
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease and cytotoxic chemotherapy is the standard of care treatment for patients with advanced disease. Here, we investigate how the microenvironment...
7.
Aughton K, Elander N, Evans A, Jackson R, Campbell F, Costello E, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830914
Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. Cytidine deaminase (CDA), inside or outside...
8.
Nayar M, Varghese C, Kanwar A, Siriwardena A, Haque A, Awan A, et al.
Gut
. 2021 Nov;
71(7):1444-1447.
PMID: 34764192
No abstract available.
9.
Marchegiani G, Barreto S, Bannone E, Sarr M, Vollmer C, Connor S, et al.
Ann Surg
. 2021 Oct;
275(4):663-672.
PMID: 34596077
Objective: The ISGPS aimed to develop a universally accepted definition for PPAP for standardized reporting and outcome comparison. Background: PPAP is an increasingly recognized complication after partial pancreatic resections, but...
10.
Baron R, Sheel A, Farooq A, Kleeff J, Contin P, Halloran C, et al.
Langenbecks Arch Surg
. 2021 Jun;
406(8):2657-2668.
PMID: 34169341
Purpose: Total pancreatectomy for severe pain in end-stage chronic pancreatitis may be the only option, but with vascular involvement, this is usually too high risk and/or technically not feasible. The...